Biotest Aktiengesellschaft (BIO.DE)
EUR 41.4
(0.49%)
EUR 41.4
(0.49%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.44 Billion EUR | 20.06% |
| 2022 | 1.2 Billion EUR | 8.95% |
| 2021 | 1.1 Billion EUR | -2.4% |
| 2020 | 1.13 Billion EUR | 2.07% |
| 2019 | 1.1 Billion EUR | 6.34% |
| 2018 | 1.04 Billion EUR | 6.52% |
| 2017 | 978.5 Million EUR | 4.9% |
| 2016 | 932.8 Million EUR | -3.11% |
| 2015 | 962.7 Million EUR | -6.77% |
| 2014 | 1.03 Billion EUR | 16.48% |
| 2013 | 886.5 Million EUR | 29.92% |
| 2012 | 682.34 Million EUR | -0.06% |
| 2011 | 682.76 Million EUR | 7.97% |
| 2010 | 632.33 Million EUR | -0.18% |
| 2009 | 633.45 Million EUR | 6.99% |
| 2008 | 592.04 Million EUR | 10.31% |
| 2007 | 536.7 Million EUR | 43.5% |
| 2006 | 374 Million EUR | 1.88% |
| 2005 | 367.09 Million EUR | 2.46% |
| 2004 | 358.27 Million EUR | 2.37% |
| 2003 | 349.97 Million EUR | -5.92% |
| 2002 | 371.99 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.44 Billion EUR | 0.17% |
| 2024 Q2 | 1.37 Billion EUR | -4.91% |
| 2023 Q2 | 1.21 Billion EUR | 2.01% |
| 2023 FY | 1.44 Billion EUR | 20.06% |
| 2023 Q4 | 1.44 Billion EUR | 7.02% |
| 2023 Q3 | 1.34 Billion EUR | 11.15% |
| 2023 Q1 | 1.19 Billion EUR | -1.06% |
| 2022 Q1 | 1.1 Billion EUR | 0.51% |
| 2022 FY | 1.2 Billion EUR | 8.95% |
| 2022 Q4 | 1.2 Billion EUR | 11.46% |
| 2022 Q3 | 1.07 Billion EUR | -2.05% |
| 2022 Q2 | 1.1 Billion EUR | -0.71% |
| 2021 Q3 | 1.13 Billion EUR | -0.91% |
| 2021 Q2 | 1.14 Billion EUR | 0.97% |
| 2021 Q1 | 1.13 Billion EUR | 0.31% |
| 2021 Q4 | 1.1 Billion EUR | -2.75% |
| 2021 FY | 1.1 Billion EUR | -2.4% |
| 2020 Q3 | 1.12 Billion EUR | -2.01% |
| 2020 FY | 1.13 Billion EUR | 2.07% |
| 2020 Q1 | 1.1 Billion EUR | -0.07% |
| 2020 Q4 | 1.13 Billion EUR | 0.81% |
| 2020 Q2 | 1.14 Billion EUR | 3.39% |
| 2019 Q4 | 1.1 Billion EUR | 1.59% |
| 2019 Q2 | 1.05 Billion EUR | 1.3% |
| 2019 Q3 | 1.09 Billion EUR | 3.1% |
| 2019 FY | 1.1 Billion EUR | 6.34% |
| 2019 Q1 | 1.04 Billion EUR | 0.22% |
| 2018 FY | 1.04 Billion EUR | 6.52% |
| 2018 Q4 | 1.04 Billion EUR | -0.5% |
| 2018 Q3 | 1.04 Billion EUR | -21.53% |
| 2018 Q2 | 1.33 Billion EUR | 31.23% |
| 2018 Q1 | 1.01 Billion EUR | 3.96% |
| 2017 FY | 978.5 Million EUR | 4.9% |
| 2017 Q4 | 978.5 Million EUR | 2.61% |
| 2017 Q3 | 953.6 Million EUR | -1.4% |
| 2017 Q2 | 967.1 Million EUR | 8.76% |
| 2017 Q1 | 889.2 Million EUR | -4.67% |
| 2016 Q1 | 968.3 Million EUR | 0.58% |
| 2016 FY | 932.8 Million EUR | -3.11% |
| 2016 Q4 | 932.8 Million EUR | -3.08% |
| 2016 Q3 | 962.4 Million EUR | -1.99% |
| 2016 Q2 | 981.9 Million EUR | 1.4% |
| 2015 Q4 | 962.7 Million EUR | -0.01% |
| 2015 FY | 962.7 Million EUR | -6.77% |
| 2015 Q1 | 1.07 Billion EUR | 3.83% |
| 2015 Q2 | 1.05 Billion EUR | -1.87% |
| 2015 Q3 | 962.8 Million EUR | -8.5% |
| 2014 Q2 | 914.3 Million EUR | 1.31% |
| 2014 FY | 1.03 Billion EUR | 16.48% |
| 2014 Q4 | 1.03 Billion EUR | 10.78% |
| 2014 Q3 | 932.1 Million EUR | 1.95% |
| 2014 Q1 | 902.5 Million EUR | 1.8% |
| 2013 Q2 | 745.8 Million EUR | 12.35% |
| 2013 Q3 | 746.5 Million EUR | 0.09% |
| 2013 Q4 | 886.5 Million EUR | 18.75% |
| 2013 FY | 886.5 Million EUR | 29.92% |
| 2013 Q1 | 663.8 Million EUR | -2.72% |
| 2012 Q3 | 672.8 Million EUR | -2.24% |
| 2012 Q4 | 682.34 Million EUR | 1.42% |
| 2012 FY | 682.34 Million EUR | -0.06% |
| 2012 Q1 | 689.5 Million EUR | 0.99% |
| 2012 Q2 | 688.2 Million EUR | -0.19% |
| 2011 Q2 | 680.8 Million EUR | 6.73% |
| 2011 FY | 682.76 Million EUR | 7.97% |
| 2011 Q3 | 721.9 Million EUR | 6.04% |
| 2011 Q4 | 682.76 Million EUR | -5.42% |
| 2011 Q1 | 637.9 Million EUR | 0.88% |
| 2010 Q4 | 632.33 Million EUR | -1.27% |
| 2010 FY | 632.33 Million EUR | -0.18% |
| 2010 Q3 | 640.5 Million EUR | -2.38% |
| 2010 Q2 | 656.1 Million EUR | 3.01% |
| 2010 Q1 | 636.9 Million EUR | 0.54% |
| 2009 FY | 633.45 Million EUR | 6.99% |
| 2009 Q4 | 633.45 Million EUR | 0.0% |
| 2008 FY | 592.04 Million EUR | 10.31% |
| 2007 FY | 536.7 Million EUR | 43.5% |
| 2006 FY | 374 Million EUR | 1.88% |
| 2005 FY | 367.09 Million EUR | 2.46% |
| 2004 FY | 358.27 Million EUR | 2.37% |
| 2003 FY | 349.97 Million EUR | -5.92% |
| 2002 FY | 371.99 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioNTech SE | 23 Billion EUR | 93.722% |
| CureVac N.V. | 788.89 Million EUR | -83.078% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 0.0% |
| BRAIN Biotech AG | 70.93 Million EUR | -1936.032% |
| Formycon AG | 890.36 Million EUR | -62.215% |
| Heidelberg Pharma AG | 70.35 Million EUR | -1952.932% |
| Medigene AG | 31.71 Million EUR | -4453.853% |